| Revenue growth | Q2 +24.9%, H1 +30% YoY |
|---|---|
| Margins | Q2 EBITDA margin 30.0% (+290bps); gross margin 65.4% |
| Demand visibility | 64 approved ANDAs; 41 pipeline molecules; 153 products pending launch |
| Management confidence | H2 'considerably better' than H1 expected |
Growth
H1 FY27 revenue ₹372.5 Cr (+30%). Q2 Regulated Markets +27.9%, Emerging Markets +21.2%, Branded Generics -20.5%.
Outlook
No numeric guidance. H2 expected 'considerably better' than H1 on launches. ₹81.17 Cr of IPO proceeds unutilised.
Risks
Branded Generics down 20.5%; Emerging Markets EBITDA ~9%; borrowings rose to ₹394.5 Cr; cash fell to ₹18 Cr.
Last quarter's promises, checked
Delivered
- Sustain ~30% EBITDA margin as minimum → Q2 30.0% (= BEAT)
Partly delivered
- FY27 revenue +30-40% → H1 +30% (= PARTIAL)
Missed
- FY27 EM EBITDA 18-20% → Q2 ~9% (= MISS)
- FY27 PAT growth 50-60% → H1 +31% (= MISS)
- Branded generics +30-40% YoY → Q2 -20.5% (= MISS)
Investor Presentation filed with BSE, NSE: SENORES. Summary written with AI assistance from the document.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,294.80
- Market cap
- ₹5,963 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 47.2×Sector 46.1×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Results Update
Senores reported Q2 FY27 revenue of ₹192 cr and EBITDA of ₹58 cr, both record highs. PAT grew 22% Y-o-Y to ₹37 cr with positive FY27 outlook.
Senores Pharmaceuticals Capacity Expansion: ₹43 Cr Investment
Senores Pharmaceuticals disclosed capacity expansion at three subsidiaries with total estimated cost of ₹43 Crore. Expansions adding ~1.5 Bn units/annum are expected by March 2027.
- Value
- ₹43.00 Cr
- Execution
- By end of March 2027
- manufacturing capacity addition (per annum)
- 1502.7 Mn units
Senores Pharmaceuticals Q2 FY27 Results: Net Profit ₹36.6 Cr, Up 21.6% YoY
Senores Pharmaceuticals Ltd reported revenue from operations of ₹192.3 Cr (+25.0% YoY) and net profit of ₹36.6 Cr (+21.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹36.6 Cr · +21.6% YoY
Senores Pharmaceuticals Board Meeting Date
Senores Pharmaceuticals has scheduled a board meeting for October 29, 2026, to approve its unaudited financial results for the quarter and half-year ended September 30, 2026.
Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals Limited has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of its Managing Director and Whole Time Director. The e-voting period concludes on November 17, 2026.
Senores Pharmaceuticals Management Change
Senores Pharmaceuticals re-appointed Swapnil Shah as MD and Chetan Shah as WTD for three-year terms. Both appointments are subject to shareholder approval via postal ballot.